{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:57Z","timestamp":1791676137786,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["26AA2006"],"award-info":[{"award-number":["26AA2006"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["LOTUS Programme (India-Japan Circulation of Talented Youths in Science) 25152858"],"award-info":[{"award-number":["LOTUS Programme (India-Japan Circulation of Talented Youths in Science) 25152858"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01730-1","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:30:18Z","timestamp":1791667818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality Analysis of FAERS Data Divergence and a Systematic Review of Comparative Safety Studies: Lessons Learned from the Example of Ranitidine and Cancer Risk"],"prefix":"10.1007","author":[{"given":"Mahesh","family":"Rathod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwari","family":"Kadari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haripriya R.","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Kasana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Katravath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-0640","authenticated-orcid":false,"given":"Masao","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-8761","authenticated-orcid":false,"given":"Krishna","family":"Undela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"1730_CR1","unstructured":"World Health Organization. Model list of essential medicines. https:\/\/list.essentialmeds.org. Accessed 22 Jan 2026."},{"key":"1730_CR2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1053\/j.gastro.2020.12.037","volume":"160","author":"ED Kantor","year":"2021","unstructured":"Kantor ED, O\u2019Connell K, Du M, Mendelsohn RB, Liang PS, Braunstein LZ. Ranitidine use and cancer risk: results from UK Biobank. Gastroenterology. 2021;160:1856-9.e5. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.037.","journal-title":"Gastroenterology"},{"key":"1730_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.14309\/ajg.0000000000001310","volume":"116","author":"CR Cardwell","year":"2021","unstructured":"Cardwell CR, McDowell RD, Hughes CM, Hicks B, Murchie P. Exposure to ranitidine and risk of bladder cancer: a nested case-control study. Am J Gastroenterol. 2021;116:1612\u20139. https:\/\/doi.org\/10.14309\/ajg.0000000000001310.","journal-title":"Am J Gastroenterol"},{"key":"1730_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2165\/00003495-198937060-00003","volume":"37","author":"SM Grant","year":"1989","unstructured":"Grant SM, Langtry HD, Brogden RN. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989;37:801\u201370. https:\/\/doi.org\/10.2165\/00003495-198937060-00003.","journal-title":"Drugs"},{"key":"1730_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1182174","volume":"13","author":"H Kang","year":"2023","unstructured":"Kang H, Nam CM, Choi D-W, Park S. Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer. Front Oncol. 2023;13:1182174. https:\/\/doi.org\/10.3389\/fonc.2023.1182174.","journal-title":"Front Oncol"},{"key":"1730_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26691-0","volume":"12","author":"K-I Joung","year":"2022","unstructured":"Joung K-I, Hwang JE, Oh I-S, Cho S-I, Shin J-Y. Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea. Sci Rep. 2022;12:22396. https:\/\/doi.org\/10.1038\/s41598-022-26691-0.","journal-title":"Sci Rep"},{"key":"1730_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40264-020-01024-0","volume":"44","author":"M Iwagami","year":"2021","unstructured":"Iwagami M, Kumazawa R, Miyamoto Y, Ito Y, Ishimaru M, Morita K, et al. Risk of cancer in association with ranitidine and nizatidine vs other H2 blockers: analysis of the Japan medical data center claims database 2005\u20132018. Drug Saf. 2021;44:361\u201371. https:\/\/doi.org\/10.1007\/s40264-020-01024-0.","journal-title":"Drug Saf"},{"key":"1730_CR8","unstructured":"US FDA. FDA approves reformulated ranitidine following comprehensive safety review. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-reformulated-ranitidine-following-comprehensive-safety-review. Accessed 22 Jan 2026."},{"key":"1730_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00228-025-03849-z","volume":"81","author":"RR Galigutta","year":"2025","unstructured":"Galigutta RR, Thomas C, Rathod M, Hasik PN, Ray RS, Prakash J, et al. Signal detection of ferric carboxymaltose-induced serious adverse events: disproportionality analysis of FAERS and VigiBase data and systematic review of case reports. Eur J Clin Pharmacol. 2025;81:1081\u201396. https:\/\/doi.org\/10.1007\/s00228-025-03849-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"1730_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psychres.2018.09.014","volume":"270","author":"LHM Arias","year":"2018","unstructured":"Arias LHM, Fadrique RS, Garc\u00eda SP, Gil MS, Lobato CT, Ortega PG. Antipsychotics and cardiovascular risk: a case\/non-case study. Psychiatry Res. 2018;270:341\u20137. https:\/\/doi.org\/10.1016\/j.psychres.2018.09.014.","journal-title":"Psychiatry Res"},{"key":"1730_CR11","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1111\/hae.14632","volume":"28","author":"DC Moore","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN. Immune checkpoint inhibitor\u2010induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system. Haemophilia. 2022;28:e145\u20138. https:\/\/doi.org\/10.1111\/hae.14632.","journal-title":"Haemophilia"},{"key":"1730_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113168","volume":"404","author":"D Cepaityte","year":"2021","unstructured":"Cepaityte D, Siafis S, Papazisis G. Safety of antipsychotic drugs: a systematic review of disproportionality analysis studies. Behav Brain Res. 2021;404:113168. https:\/\/doi.org\/10.1016\/j.bbr.2021.113168.","journal-title":"Behav Brain Res"},{"key":"1730_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"key":"1730_CR14","unstructured":"US FDA. FDA Adverse Event Reporting System (FAERS) public dashboard. https:\/\/www.fda.gov \/drugs\/questions-and-answers-\/fda-adverse- event-reporting-system-faers-public-dashboard. Accessed 22 Jan 2026."},{"key":"1730_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"key":"1730_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912469","volume":"19","author":"C-H Wang","year":"2022","unstructured":"Wang C-H, Chen II, Chen C-H, Tseng Y-T. Pharmacoepidemiological research on N-nitrosodimethylamine-contaminated ranitidine use and long-term cancer risk: a population-based longitudinal cohort study. Int J Environ Res Public Health. 2022;19:12469. https:\/\/doi.org\/10.3390\/ijerph191912469.","journal-title":"Int J Environ Res Public Health"},{"key":"1730_CR17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/apt.16464","volume":"54","author":"YD Kim","year":"2021","unstructured":"Kim YD, Wang J, Shibli F, Poels KE, Ganocy SJ, Fass R. No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies. Aliment Pharmacol Ther. 2021;54:606\u201315. https:\/\/doi.org\/10.1111\/apt.16464.","journal-title":"Aliment Pharmacol Ther"},{"key":"1730_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","volume":"47","author":"CA Gravel","year":"2024","unstructured":"Gravel CA, Bai W, Douros A. Comparators in pharmacovigilance: a quasi-quantification bias analysis. Drug Saf. 2024;47:809\u201319. https:\/\/doi.org\/10.1007\/s40264-024-01433-5.","journal-title":"Drug Saf"},{"key":"1730_CR19","doi-asserted-by":"publisher","first-page":"e2333495","DOI":"10.1001\/jamanetworkopen.2023.33495","volume":"6","author":"SC You","year":"2023","unstructured":"You SC, Seo SI, Falconer T, Yanover C, Duarte-Salles T, Seager S, et al. Ranitidine use and incident cancer in a multinational cohort. JAMA Netw Open. 2023;6:e2333495. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.33495.","journal-title":"JAMA Netw Open"},{"key":"1730_CR20","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s10620-021-06972-w","volume":"67","author":"S Kumar","year":"2022","unstructured":"Kumar S, Goldberg DS, Kaplan DE. Ranitidine use and gastric cancer among persons with Helicobacter pylori. Dig Dis Sci. 2022;67:1822\u201330. https:\/\/doi.org\/10.1007\/s10620-021-06972-w.","journal-title":"Dig Dis Sci"},{"key":"1730_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/(SICI)1099-1557(200003\/04)9:2<149::AID-PDS481>3.0.CO;2-1","volume":"9","author":"LA Habel","year":"2000","unstructured":"Habel LA, Levin TR, Friedman GD. Cimetidine use and risk of breast, prostate, and other cancers. Pharmacoepidemiol Drug Saf. 2000;9:149\u201355. https:\/\/doi.org\/10.1002\/(SICI)1099-1557(200003\/04)9:2%3c149::AID-PDS481%3e3.0.CO;2-1.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1730_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004842","volume":"23","author":"IO Sawaid","year":"2026","unstructured":"Sawaid IO, Din Z, Golan E, Ruppin E, Golan-Cohen A, Green I, et al. Association between proton pump inhibitor use and upper gastrointestinal cancer: a matched case-control study accounting for reverse causation and confounding by indication. PLoS Med. 2026;23:e1004842. https:\/\/doi.org\/10.1371\/journal.pmed.1004842.","journal-title":"PLoS Med"},{"key":"1730_CR23","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i1.99240","volume":"16","author":"A Krishnan","year":"2025","unstructured":"Krishnan A, Schneider CV, Walsh D. Proton pump inhibitors and all-cause mortality risk among cancer patients. World J Clin Oncol. 2025;16:99240. https:\/\/doi.org\/10.5306\/wjco.v16.i1.99240.","journal-title":"World J Clin Oncol"},{"key":"1730_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0277-5379(88)90247-7","volume":"24","author":"C Burtin","year":"1988","unstructured":"Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol. 1988;24:161\u20137. https:\/\/doi.org\/10.1016\/0277-5379(88)90247-7.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"1730_CR25","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1136\/bmj.290.6485.1850","volume":"290","author":"MJ Langman","year":"1985","unstructured":"Langman MJ. Antisecretory drugs and gastric cancer. Br Med J (Clin Res Ed). 1985;290:1850\u20132. https:\/\/doi.org\/10.1136\/bmj.290.6485.1850.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1730_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0140-6736(90)91888-H","volume":"336","author":"C La Vecchia","year":"1990","unstructured":"La Vecchia C, Negri E, D\u2019Avanzo B, La Vecchia C, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet. 1990;336:355\u20137. https:\/\/doi.org\/10.1016\/0140-6736(90)91888-H.","journal-title":"Lancet"},{"key":"1730_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/00365528509093755","volume":"111","author":"F Di Mario","year":"1985","unstructured":"Di Mario F, Farinati F, Cardin F. The risk of gastric dysplasia in medical long-term treatment of peptic ulcer disease. Scand J Gastroenterol Suppl. 1985;111:31\u20135. https:\/\/doi.org\/10.3109\/00365528509093755.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"1730_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01771458","volume":"32","author":"HJ Nielsen","year":"1990","unstructured":"Nielsen HJ, Nielsen H, Moesgaard F, Tvede N, Klarlund K, Mansa B, et al. The effect of ranitidine on cellular immunity in patients with multiple myeloma. Cancer Immunol Immunother. 1990;32:201\u20135. https:\/\/doi.org\/10.1007\/BF01771458.","journal-title":"Cancer Immunol Immunother"},{"key":"1730_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010024","volume":"13","author":"G McGwin","year":"2020","unstructured":"McGwin G. The association between ranitidine use and gastrointestinal cancers. Cancers (Basel). 2020;13:24. https:\/\/doi.org\/10.3390\/cancers13010024.","journal-title":"Cancers (Basel)"},{"key":"1730_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5832","volume":"367","author":"E Mahase","year":"2019","unstructured":"Mahase E. FDA recalls ranitidine medicines over potential cancer causing impurity. BMJ. 2019;367:l5832. https:\/\/doi.org\/10.1136\/bmj.l5832.","journal-title":"BMJ"},{"key":"1730_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9081071","volume":"9","author":"S Kim","year":"2021","unstructured":"Kim S, Lee S, Hong J, Ko I, Kim J-Y, Kim D-K. Effect of ranitidine intake on the risk of gastric cancer development. Healthcare (Basel). 2021;9:1071. https:\/\/doi.org\/10.3390\/healthcare9081071.","journal-title":"Healthcare (Basel)"},{"key":"1730_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16:359\u201365. https:\/\/doi.org\/10.1002\/pds.1323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1730_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1730_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","volume":"49","author":"M Fusaroli","year":"2026","unstructured":"Fusaroli M, Sartori D, Van Puijenbroek EP, Nor\u00e9n GN. Charting and sidestepping the pitfalls of disproportionality analysis. Drug Saf. 2026;49:147\u201362. https:\/\/doi.org\/10.1007\/s40264-025-01604-y.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01730-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:04:29Z","timestamp":1791673469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01730-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":34,"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01730-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Masao Iwagami is an Editorial Board member of\n                      Drug Safety\n                      . Masao Iwagami was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Mahesh Rathod, Maheshwari Kadari, Haripriya R. Mohan, Ruby Kasana, Mounika Katravath, and Krishna Undela have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}